Patent 10335466 was granted and assigned to Voyager Therapeutics on July, 2019 by the United States Patent and Trademark Office.
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment of Parkinson's Disease.